Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates

Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $15.00 price target on Biohaven Pharma (NYSE: BHVN)

The analyst commented, "Biohaven reported 4Q25 numbers and highlighted progress across its three prioritized franchises, including degraders BHV-1400 in IgAN and BHV-1300 in Graves’ disease, opakalim in focal onset epilepsy, and taldefgrobep in obesity. With two pivotal trial initiations for the degraders and a pivotal readout for opakalim in FOS expected in 2026, we are supportive of the company’s more focused pipeline and remain optimistic for the data. The company ended the quarter with $322M in cash but continued to be opportunistic with fundraising as it already added another ~$180M in early 1Q26. We have updated our model for this recent print and financings and adjusted our EPS estimates from -$3.45 to -$2.85 for 2026 and from -$2.40 to -$2.15 in 2027, and we remain Outperform."

For an analyst ratings summary and ratings history on Biohaven Pharma click here. For more ratings news on Biohaven Pharma click here.

Shares of Biohaven Pharma closed at $11.81 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Greenway Technologies board member Raymond Wright resigns
• Bitmine Immersion Technologies plans $300 million preferred stock offering